 BEDMER, N.J., Nov. 20, 2020 GLOBE NEWSWIRE -- Matinas BioPharma Holdings, Inc. NYSE AMER: MTNB, a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that it has been awarded up to 3.75 million from the Cystic Fibrosis Foundation CFF. The award will support preclinical development of MAT2501, Matinas lipid nano-crystal LNC oral formulation of the broad-spectrum aminoglycoside amikacin, toward an indication to treat nontuberculous mycobacterial NTM lung disease, including infections in patients with cystic fibrosis CF. 